Table 3. Univariate and multivariate analyses of event-free survival after frontline treatments in all patients with POALs.
| Factors | Relative risk | 95% Cl | P value |
|---|---|---|---|
| Univariate analysis | |||
| Age > 60 years | 3.720 | 1.184–11.691 | 0.025 |
| Locations | |||
| Conjunctiva | 1 | ||
| Orbital | 0.311 | 0.062–1.559 | 0.155 |
| Lacrimal gland | 1.016 | 0.273–3.788 | 0.981 |
| High-grade components | 3.483 | 1.185–10.237 | 0.023 |
| LDH elevation | 3.281 | 1.357–10.759 | 0.011 |
| Ann Arbor stage III–IV disease | 4.293 | 1.464–12.590 | 0.008 |
| AJCC stage T3 and T4 disease | 4.254 | 1.503–12.042 | 0.006 |
| AJCC stage with N1–4 disease | 5.191 | 1.608–16.764 | 0.006 |
| AJCC stage with M1 disease | 2.538 | 0.715–9.012 | 0.150 |
| Multivariate analysis | |||
| Age > 60 years | 4.441 | 1.133–17.400 | 0.032 |
Abbreviations: POALs, primary ocular adnexal lymphomas; CI, confidence interval; LDH, lactate dehydrogenase; AJCC, American Joint Committee on Cancer.